USFDA closes inspection at Alembic Pharma's Vadodara bioequivalence facility

Regulatory & Legal View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹824.20

prior close

₹830.00

announcement price

After-mkt

timing

Nifty Microcap 250market+0.8%-0.5% vs market

Pharmaceuticals peers, median of 173sector+1.0%-0.7% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.7

15m

+0.5

30m

+3.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4+0.8-0.5+1.0-0.7

Next day

+2.5+2.5+0.1+1.7+0.8

+2.6+2.3+0.3+2.2+0.5

+2.1+2.8-0.6+1.9+0.3

+2.4+4.1-1.7+2.8-0.4

+3.1+2.5+0.6+1.7+1.4

+3.6+1.2+2.4+0.3+3.3

15d

-2.8-0.8-2.0-3.1+0.2

-3.1-1.7-1.4-4.4+1.4

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA has issued an Establishment Inspection Report (EIR) and formally closed the inspection of Alembic Pharmaceuticals' Bioequivalence Facility at Vadodara, Gujarat. The inspection was conducted from March 3 to March 7, 2025. EIR closure means the facility has met USFDA standards, clearing a regulatory overhang and supporting continued US product approvals from this site.

Likely market impact

Positive for shareholders: EIR closure removes regulatory uncertainty, supports ongoing US exports and future ANDA approvals from this facility.